- In April 2025, a project led by Stanford doctoral student Guy Lutsker introduced an AI‑powered “digital twin” capable of predicting health events like diabetes onset by analyzing personal medical records and glucose trends—marking a leap forward in personalized disease prevention
- In April 2025, Medi‑Tech Insights reported that the global digital twin in healthcare market is projected to grow at a robust 30–50% CAGR, fueled by rising demand for personalized therapies and significant venture capital investment
- A new initiative from Stanford’s Center for Biomedical Informatics Research detailed how medical digital twins—combining AI with mechanistic models—are being designed to simulate patient physiology for conditions ranging from diabetes to cancer, enabling personalized treatment planning
- In April 2025, MD Anderson Cancer Center released a report explaining how “digital twins” are being used to model tumor behavior, allowing oncologists to evaluate multiple treatment strategies in silico before applying them clinically
- In October 2023, Leucine, a startup, raised USD 7 million in Series ‘A’ funding to grow its AI-driven digital twin platform. The platform is designed to help drug manufacturers streamline regulatory compliance by replacing paper-based records and legacy systems. Leucine's platform functions as a digital twin of a drug maker's production floor, utilizing AI to digitize manufacturing workflows and improve compliance, speed, and cost-effectiveness
